Tylenol Pregnancy Warning: Where the FDA Label Change Stands in 2026

In September 2025, federal health officials announced steps toward a Tylenol pregnancy warning about a possible link between acetaminophen use during pregnancy and autism or ADHD in children. The announcement sparked strong reactions from doctors, researchers and the drug’s maker, and it arrived in the middle of ongoing litigation. This article explains what the FDA actually said, where the label change process stands as of October 2026, what the research shows, and how it connects to the Tylenol autism lawsuits.

Direct2Attorney is a legal marketing and referral service, not a law firm, and we do not give legal or medical advice. A participating law firm decides whether it can take any case. If you are pregnant, talk with your doctor before starting or stopping any medication.

What the FDA Said About a Tylenol Pregnancy Warning

On September 22, 2025, the FDA announced that it had begun the process to change labeling for acetaminophen to reflect evidence suggesting a possible association between use during pregnancy and an increased risk of neurological conditions such as autism and ADHD in children. The agency also sent a letter to physicians nationwide.

Two points in the FDA’s statement are easy to miss but important:

• The FDA stated that a causal relationship has not been established
• The FDA acknowledged that acetaminophen is the only over-the-counter drug approved for treating fever during pregnancy, and that untreated fever can itself pose risks

In other words, the FDA described an association that it believed doctors and patients should be aware of. It did not say acetaminophen causes autism, and it did not tell pregnant women never to use it.

Where the Label Change Stands as of October 2026

Most acetaminophen products sold without a prescription, including Tylenol, are regulated under the FDA’s over-the-counter (OTC) monograph system. Changing OTC monograph labeling generally involves a formal process, which can include a proposed order, a public comment period and a final order.

Based on our review of publicly available information as of October 2026, we have not found a final FDA order adding a neurodevelopmental warning to OTC acetaminophen labels. Standard OTC labels continue to advise people who are pregnant or breastfeeding to ask a health professional before use. Citizen petitions asking the FDA to require a specific warning have been filed, and Kenvue, which sells Tylenol, submitted a response in October 2025 arguing that a label change is not supported by scientific evidence.

Because the process can change, check the FDA’s website or ask your pharmacist for the current label information.

How Medical Groups Responded

Leading obstetric organizations disagreed with the federal framing. The Society for Maternal-Fetal Medicine said in September 2025 that the evidence linking acetaminophen to autism or ADHD is inconclusive and that acetaminophen remains an appropriate option for treating pain and fever during pregnancy. The American College of Obstetricians and Gynecologists (ACOG) said the announcement was not backed by the full body of scientific evidence.

Both groups emphasized a point most experts agree on: pregnant women should not stop or avoid needed treatment without talking to their clinician, because untreated high fever and severe pain can carry their own risks.

What the Research Shows

The science on acetaminophen and neurodevelopment is mixed, and different study designs point in different directions. Two widely discussed studies illustrate the debate.

The 2024 Swedish sibling study

In April 2024, researchers published a study in JAMA that followed about 2.48 million children born in Sweden. When they looked at the whole population, they saw a small association between acetaminophen exposure and autism or ADHD. But when they compared siblings within the same families, which helps account for shared genetics and home environment, the association disappeared. The NIH summarized the study as finding no causal link.

The 2025 Mount Sinai and Harvard review

In August 2025, researchers from Mount Sinai and the Harvard T.H. Chan School of Public Health published a review of 46 studies in Environmental Health. They concluded that higher-quality studies were more likely to show an association, while stressing that their findings show association rather than proof of causation. They recommended cautious, time-limited use under medical guidance. One of the authors has also served as an expert for plaintiffs in the litigation.

Why the studies disagree

• Observational studies can show associations but cannot by themselves prove cause and effect
• Factors like the reason a mother took acetaminophen (fever, infection, pain) may themselves be linked to child outcomes
• Genetics strongly influence autism and ADHD, which sibling comparisons try to account for
• Studies measure exposure differently, from self-reports to biomarkers

How a Tylenol Pregnancy Warning Connects to the Lawsuits

The Tylenol autism lawsuits allege that manufacturers and retailers knew or should have known about the possible risk and failed to warn pregnant consumers. A label change would not by itself prove those claims, and the absence of one would not by itself defeat them. But it is part of the broader context.

Here is where the main litigation stands as of October 2026:

• Federal MDL 3043: in December 2023, Judge Denise Cote in the Southern District of New York excluded the plaintiffs’ general causation experts, leading to dismissal of the federal cases
• Second Circuit appeal: on July 13, 2026, the U.S. Court of Appeals for the Second Circuit vacated those judgments and sent the cases back, finding that several experts were improperly excluded. The court did not decide whether acetaminophen causes autism or ADHD
• Rehearing request: defendants have asked the Second Circuit to rehear the case, and that request was reported as pending in September 2026
• Texas lawsuit: the Texas attorney general sued Johnson & Johnson and Kenvue in October 2025 under the state’s consumer protection law. A state judge denied a motion to dismiss in early 2026, and jurisdiction issues have been argued on appeal

For a deeper look at the appellate decision, read our article on the Tylenol autism lawsuit Second Circuit ruling.

Questions to Ask Your Doctor

The debate over a Tylenol pregnancy warning can feel confusing if you are pregnant now or planning a pregnancy. A short conversation with your obstetrician or midwife can help you make decisions that fit your health. Questions you might ask include:

• When is acetaminophen appropriate for me during pregnancy, and at what dose?
• How long should I use it before calling you?
• What are the risks of an untreated fever or severe pain for me and my baby?
• Are there non-medication options I can try for headaches or minor pain?
• Which other pain relievers should I avoid during pregnancy, and why?

Your clinician knows your medical history and can weigh the benefits and risks for your specific situation. The FDA itself noted that untreated high fever can pose risks during pregnancy, which is one reason medical guidance matters more than headlines.

If your child has already been diagnosed

Parents of children with autism or ADHD sometimes feel guilt after reading news about acetaminophen. It is important to remember that autism and ADHD have many contributing factors, including strong genetic influences, and the science on acetaminophen remains disputed. Taking medicine for pain or fever as directed is not a personal failing. Support for your child, such as therapy, school services and family resources, is the priority. Questions about legal options can come later, on your own timeline.

Who May Want a Case Review

Participating law firms evaluate each case individually. Families who ask about a Tylenol autism claim typically have circumstances like these:

• The mother used acetaminophen during pregnancy, often regularly or over an extended period
• A child was later diagnosed with autism spectrum disorder or ADHD by a qualified professional
• There are records, or reliable recollection, of acetaminophen use during pregnancy
• The claim may still be timely under state law

A firm may decline a case for many reasons, including legal developments in the litigation. No one can guarantee compensation, and the science remains disputed.

Records That Can Help

If you are considering a review, these records may be useful:

• Prenatal care records that mention medications, fever, pain or illness
• Pharmacy or store receipts, if available
• Your child’s diagnostic evaluation for autism or ADHD
• Developmental, therapy and school support records
• A written timeline of acetaminophen use by trimester, to the best of your memory

Be honest about uncertainty

Few people track over-the-counter medicine use during pregnancy. It is fine to say you are unsure. Law firms are used to working with incomplete records, and accuracy is more helpful than guesses.

Deadlines and Timing

Statutes of limitations vary by state. For claims on behalf of a child, many states extend the deadline until the child reaches adulthood, but rules differ and some have exceptions. The litigation’s procedural posture can also affect timing strategy. A participating law firm can explain how deadlines may apply in your state.

Frequently Asked Questions

Did the FDA add a Tylenol pregnancy warning to the label?

The FDA announced in September 2025 that it had started the process. As of October 2026, we have not found a final order adding a new neurodevelopmental warning to OTC labels. Check with your pharmacist or the FDA for the latest information.

Is it safe to take Tylenol while pregnant?

That is a medical question for your doctor. Major obstetric groups continue to consider acetaminophen an appropriate option for pain and fever when used as directed, and they caution against stopping needed treatment without medical advice.

Did the FDA say Tylenol causes autism?

No. The FDA stated that a causal relationship has not been established. It described a possible association.

Are the Tylenol autism lawsuits active again?

The Second Circuit revived the federal cases in July 2026, but defendants have sought rehearing. The litigation is ongoing and could change.

Does a review cost anything?

No. Requesting a review through Direct2Attorney is free and confidential, and you are not obligated to proceed.

Which companies are named in the Tylenol lawsuits?

The federal cases have named Kenvue, the company that now sells Tylenol, along with retailers that sold store-brand acetaminophen, such as Walmart, CVS, Walgreens and Target. The Texas attorney general’s case names Johnson & Johnson and Kenvue. Which defendants apply to a particular family depends on the products used.

Will the label change affect my claim?

Not directly. A future Tylenol pregnancy warning would not automatically prove past claims, and courts decide legal questions such as causation separately. A participating law firm can explain how developments might matter for your situation.

The Bottom Line

The push for a Tylenol pregnancy warning reflects an ongoing scientific debate, not a settled conclusion. The FDA started a label change process but stated that causation has not been established, medical groups disagree with the federal framing, and the lawsuits were revived on appeal in 2026. If your family is affected, gather prenatal and diagnostic records and consider a review. Learn more on our Tylenol autism lawsuit page.

Think you may qualify? See if you qualify for a free, confidential Tylenol Autism case review →

This article is general information, not legal or medical advice. Direct2Attorney is not a law firm. Requesting a review does not create an attorney-client relationship, and no outcome or compensation is guaranteed.